- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|GSK 2334470 | GSK-2334470|
|GSK2334470 is a novel 3-phosphoinositide dependent protein kinase 1 (PDK1) inhibitor. Its discovery is described in , where it is compound 28d.
The PDK1/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumour angiogenesis and represents a promising target for oncology therapeutics [1,3].
|CAS Registry No.||1227911-45-6|
|GtoPdb PubChem SID||249565688|
|Search Google for chemical match using the InChIKey||QLPHOXTXAKOFMU-WBVHZDCISA-N|
|Search Google for chemicals with the same backbone||QLPHOXTXAKOFMU|
|Search UniChem for chemical match using the InChIKey||QLPHOXTXAKOFMU-WBVHZDCISA-N|
|Search UniChem for chemicals with the same backbone||QLPHOXTXAKOFMU|
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.✖
Cat. No. 4143